Posterior reversible encephalopathy syndrome induced by anti-VEGF agents

Targeted Oncology

Volumn 6, Issue 4, 2011, Pages 253-258

  Tlemsani, Camille ^a   Mir, Olivier ^a   Boudou Rouquette, Pascaline ^a   Huillard, Olivier ^a   Maley, Karin ^a   Ropert, Stanislas ^a   Coriat, Romain ^a   Goldwasser, François ^a  

^a Université Paris Descartes ^*  (France)

Author keywords

Angiogenesis inhibitors; Cancer; Outcomes; Reversible posterior leukoencephalopathy syndrome; VEGF A

Indexed keywords

BEVACIZUMAB; PROTEIN TYROSINE KINASE INHIBITOR; SORAFENIB; SUNITINIB; VASCULOTROPIN INHIBITOR;

ARTICLE; BLOOD PRESSURE MONITORING; BLOOD PRESSURE REGULATION; CONVULSION; DIASTOLIC BLOOD PRESSURE; DIGESTIVE SYSTEM CANCER; DISEASE COURSE; DRUG SAFETY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; GASTROINTESTINAL STROMAL TUMOR; HEADACHE; HUMAN; HYPERTENSION; KIDNEY CARCINOMA; MULTIPLE CYCLE TREATMENT; POSTERIOR REVERSIBLE ENCEPHALOPATHY SYNDROME; PRIORITY JOURNAL; PROTEINURIA; RETINA MACULA AGE RELATED DEGENERATION; RISK ASSESSMENT; SEIZURE; SYSTEMATIC REVIEW; VISUAL DISORDER;

ANGIOGENESIS INHIBITORS; FEMALE; HUMANS; MALE; POSTERIOR LEUKOENCEPHALOPATHY SYNDROME; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84856029091     PISSN: 17762596     EISSN: 1776260X     Source Type: Journal    
DOI: 10.1007/s11523-011-0201-x     Document Type: Article

References (37)

1. Feske SK (2011) Posterior reversible encephalopathy syndrome: a review. Semin Neurol 31(2):202-215
2. Hinchey J, Chaves C, Appignani B, Breen J, Pao L, Wang A et al (1996) A reversible posterior leukoencephalopathy syndrome. N Engl J Med 334(8):494-500 (Pubitemid 26067737)
3. Hinchey JA (2008) Reversible posterior leukoencephalopathy syndrome: what have we learned in the last 10 years? Arch Neurol 65(2):175-176 (Pubitemid 351240776)
4. Glusker P, Recht L, Lane B (2006) Reversible posterior leukoencephalopathy syndrome and bevacizumab. N Engl J Med 354(9):980-982, discussion 980-982
5. Govindarajan R, Adusumilli J, Baxter DL, El-Khoueiry A, Harik SI (2006) Reversible posterior leukoencephalopathy syndrome induced by RAF kinase inhibitor BAY 43-9006. J Clin Oncol 24 (28):e48
6. Kapiteijn E, Brand A, Kroep J, Gelderblom H (2007) Sunitinib induced hypertension, thrombotic microangiopathy and reversible posterior leukencephalopathy syndrome. Ann Oncol 18(10):1745-1747 (Pubitemid 47506266)
7. Leighl NB, Raez LE, Besse B, Rosen PJ, Barlesi F, Massarelli E et al (2010) A multicenter, phase 2 study of vascular endothelial growth factor trap (Aflibercept) in platinum- and erlotinibresistant adenocarcinoma of the lung. J Thorac Oncol 5 (7):1054-1059
8. Mir O, Ropert S, Alexandre J, Goldwasser F (2009) Hypertension as a surrogate marker for the activity of anti-VEGF agents. Ann Oncol 20(5):967-970
9. Mir O, Coriat R, Ropert S, Cabanes L, Blanchet B, Camps S et al (2010) Treatment of bevacizumab-induced hypertension by amlodipine. Invest New Drugs. doi:10.1007/s10637-010-9549-5
10. Scappaticci FA, Skillings JR, Holden SN, Gerber HP, Miller K, Kabbinavar F et al (2007) Arterial thromboembolic events in patients with metastatic carcinoma treated with chemotherapy and bevacizumab. J Natl Cancer Inst 99(16):1232-1239 (Pubitemid 47299901)
11. Dogan E, Aksoy S, Arslan C, Dede DS, Altundag K (2009) Probable sorafenib-induced reversible encephalopathy in a patient with hepatocellular carcinoma. Med Oncol 27(4):1436-1437
12. Rini BI, Garcia JA, Cooney MM, Elson P, Tyler A, Beatty K et al (2009) A phase I study of sunitinib plus bevacizumab in advanced solid tumors. Clin Cancer Res 15(19):6277-6283
13. Artunay O, Yuzbasioglu E, Rasier R, Sengul A, Bahcecioglu H (2010) Posterior reversible encephalopathy syndrome after intravitreal bevacizumab injection in patient with choroidal neovascular membrane secondary to age-related maculopathy. J Ocul Pharmacol Ther 26(3):301-303
14. Burki F, Badie K, Bartoli P, Bernard P, Montastruc JL, Bagheri H (2008) Reversible posterior leukoencephalopathy syndrome associated with bevacizumab/doxorubicin regimen. Br J Clin Pharmacol 65(5):793-794 (Pubitemid 351535098)
15. Chang Y, Mbeo G, Littman SJ (2011) Reversible posterior leukoencephalopathy syndrome associated with concurrent bevacizumab, gemcitabine, and oxaliplatin for cholangiocarcinoma. J Gastrointest Cancer. doi:10.1007/s12029-011-9279-8
16. Chen A, Agarwal N (2009) Reversible posterior leucoencephalopathy syndrome associated with sunitinib. Intern Med J 39 (5):341-342
17. Cumurciuc R, Martinez-Almoyna L, Henry C, Husson H, de Broucker T (2008) Posterior reversible encephalopathy syndrome during sunitinib therapy. Rev Neurol (Paris) 164(6-7):605-607 (Pubitemid 351893095)
18. dos Reis Simões da Silva FM, Burgos Pêgo PM, Henriques Vendrell MC, de Azevedo Batalha Ferreira dos Santos Farias MJ, Ribeiro Timóteo AC, Martins da Costa MC, Monteiro Barbosa Moreira Cravo IM, Ribeiro Gomes FM (2011) Posterior Reversible Encephalopathy Syndrome and Anti-Angiogenic Agents: A Case Report. Neuro-ophtalmology 35(1):32-37
19. El Maalouf G, Mitry E, Lacout A, Lievre A, Rougier P (2008) Isolated brainstem involvement in posterior reversible leukoencephalopathy induced by bevacizumab. J Neurol 255(2):295-296
20. Feldman DR, Baum MS, Ginsberg MS, Hassoun H, Flombaum CD, Velasco S et al (2009) Phase I trial of bevacizumab plus escalated doses of sunitinib in patients with metastatic renal cell carcinoma. J Clin Oncol 27(9):1432-1439
21. Koopman M, Muller EW, Punt CJ (2008) Reversible posterior leukoencephalopathy syndrome caused by bevacizumab: report of a case. Dis Colon Rectum 51(9):1425-1426
22. Lau PC, Paunipagar B (2011) Posterior reversible encephalopathy syndrome with bevacizumab. Hong Kong Med J 17(1):80-81
23. Martin G, Bellido L, Cruz JJ (2007) Reversible posterior leukoencephalopathy syndrome induced by sunitinib. J Clin Oncol 25(23):3559 (Pubitemid 47310905)
24. Ozcan C, Wong SJ, Hari P (2006) Reversible posterior leukoencephalopathy syndrome and bevacizumab. N Engl J Med 354 (9):980-982, discussion 980-982
25. Padhy BM, Shanmugam SP, Gupta YK, Goyal A (2011) Reversible posterior leucoencephalopathy syndrome in an elderly male on sunitinib therapy. Br J Clin Pharmacol 71(5):777-779
26. Peter S, Hausmann N, Schuster A, Boehm HF (2008) Reversible posterior leukoencephalopathy syndrome and intravenous bevacizumab. Clin Experiment Ophthalmol 36(1):94-96 (Pubitemid 351285202)
27. van der Veldt AA, van den Eertwegh AJ, Hoekman K, Barkhof F, Boven E (2007) Reversible cognitive disorders after sunitinib for advanced renal cell cancer in patients with preexisting arteriosclerotic leukoencephalopathy. Ann Oncol 18(10):1747-1750 (Pubitemid 47506267)
28. Medioni J, Cojocarasu O, Banu E, Cassar-Queudeville A, Halimi P, Oudard S (2007) Reversible encephalopathy syndrome secondary to sunitinib for metastatic renal cell carcinoma patient. Targ Oncol 2(3):193-195
29. Lou E, Turner S, Sumrall A, Reardon DA, Desjardins A, Peters KB et al (2011) Bevacizumab-induced reversible posterior leukoencephalopathy syndrome and successful retreatment in a patient with glioblastoma. J Clin Oncol. doi:10.1200/ JCO.2011.36.1865
30. Seet RC, Rabinstein AA (2011) Clinical features and outcomes of posterior reversible encephalopathy syndrome following bevacizumab treatment. QJM. doi:10.1093/qjmed/hcr139
31. Pinedo DM, Shah-Khan F, Shah PC (2007) Reversible posterior leukoencephalopathy syndrome associated with oxaliplatin. J Clin Oncol 25(33):5320-5321 (Pubitemid 350232266)
32. Paker AM, Chi L, Ruiz MC, Loghin ME (2011) Posterior reversible encephalopathy syndrome in patients with cancer. J Clin Oncol 29(suppl):2561
33. Plouet J, Schilling J, Gospodarowicz D (1989) Isolation and characterization of a newly identified endothelial cell mitogen produced by AtT-20 cells. EMBO J 8(12):3801-3806 (Pubitemid 20016061)
34. Izzedine H, Ederhy S, Goldwasser F, Soria JC, Milano G, Cohen A et al (2009) Management of hypertension in angiogenesis inhibitor-treated patients. Ann Oncol 20(5):807-815
35. Tsatsaris V, Goffin F, Munaut C, Brichant JF, Pignon MR, Noel A et al (2003) Overexpression of the soluble vascular endothelial growth factor receptor in preeclamptic patients: pathophysiological consequences. J Clin Endocrinol Metab 88 (11):5555-5563 (Pubitemid 37452769)
36. Patel TV, Morgan JA, Demetri GD, George S, Maki RG, Quigley M et al (2008) A preeclampsia-like syndrome characterized by reversible hypertension and proteinuria induced by the multitargeted kinase inhibitors sunitinib and sorafenib. J Natl Cancer Inst 100(4):282-284 (Pubitemid 351480534)
37. Wagner SJ, Acquah LA, Lindell EP, Craici IM, Wingo MT, Rose CH et al (2011) Posterior reversible encephalopathy syndrome and eclampsia: pressing the case for more aggressive blood pressure control. Mayo Clin Proc 86(9):851-856